Broadwood opposes revised STAAR Surgical acquisition by Alcon
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Axsome Therapeutics (AXSM) PT Raised to $380 at Jefferies
Broadwood Partners Responds to Alcon’s Increase to Proposed Acquisition Price of STAAR Surgical
December 9, 2025 12:39 PM ESTNotes That Price Bump Is Further Evidence That the Original Sale Process Was Horribly Flawed and Failed to Maximize Shareholder Value
New Price Is Approximately Half the Price Offered by Alcon Twice in 2024; STAARs Projections Have Not Changed Materially
Continues to Urge STAAR Shareholders to Vote AGAINST the Proposed Transaction
NEW YORK--(BUSINESS WIRE)-- Broadwood Partners, L.P. and its affiliates (collectively, Broadwood, we, us or our) today responded to the amended transaction terms of the proposed acquisition of STAAR Surgical Company (STAAR or the Company) (NASDAQ:... More
